Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.
Current Team (5)Update
Past Team (2)Update
Funding Rounds (4) - $64.4MUpdate
A venture capital firm
ROTH Capital Partners is an investment banking firm dedicated to the small-cap public market.
Thomas, McNerney & Partners is a health care venture capital firm with approximately $600...
BDC Venture Capital is a major venture capital investor in Canada, active at every stage of the...
Canadian Venture Capital Firm
With over $1.5 billion under management, TL Ventures have been actively engaged in the business...
Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads...
Ventures West is one of Canada's largest privately owned venture capital companies. In...
303B College Road East
Princeton, NJ 08540